Mankind Pharma signs India licensing deal for ensartinib

The agreement with Betta Pharmaceuticals covers development, manufacturing, registration and commercialisation in India, subject to applicable approvals.

Mankind Pharma signs India licensing deal for ensartinib

Mankind Pharma has signed an agreement with Betta Pharmaceuticals for exclusive India rights to develop, manufacture, register and commercialise ensartinib, a targeted oncology drug.

The company said the deal includes an upfront payment, potential development and sales milestone payments, and royalties on annual net sales in India. It did not disclose the amounts or royalty rate.

The US Food and Drug Administration approved ensartinib in December 2024 for certain adults with ALK-positive locally advanced or metastatic non-small cell lung cancer who had not previously received an ALK inhibitor. Mankind said introduction in India remains subject to regulatory approvals and commercial and operational requirements.